Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis

Shinji Sato, Michito Hirakata, Masataka Kuwana, Akira Suwa, Shinichi Inada, Tsuneyo Mimori, Takeji Nishikawa, Chester V. Oddis, Yasuo Ikeda

Research output: Contribution to journalArticle

327 Citations (Scopus)

Abstract

Objective. To identify novel autoantibodies specific for dermatomyositis (DM), especially those specific for clinically amyopathic DM (C-ADM). Methods. Autoantibodies were analyzed by immunoprecipitation in 298 serum samples from patients with various connective tissue diseases (CTDs) or idiopathic pulmonary fibrosis (IPF). Antigen specificity of the sera was further examined by immunoblotting and indirect immunofluorescence (IF). The disease specificity and clinical features associated with the antibody of interest were determined. Results. Eight sera recognized a polypeptide of ∼140 kd (CADM-140 autoantigen) by immunoprecipitation and immunoblotting. Immunoreactivity was detected in the cytoplasm, and indirect IF revealed a granular or reticular pattern. Anti-CADM-140 antibodies were detected in 8 of 42 patients with DM, but not in patients with other CTDs or IPF. Interestingly, all 8 patients with anti-CADM-140 antibodies had C-ADM. Among 42 patients with DM, those with anti-CADM-140 autoantibodies had significantly more rapidly progressive interstitial lung disease (ILD) when compared with patients without anti-CADM-140 autoantibodies (50% versus 6%; P = 0.008). Conclusion. These results indicate that the presence of anti-CADM-140 autoantibodies may be a novel marker for C-ADM. Further attention should be directed to the detection of rapidly progressive ILD in those patients with anti-CADM-140 autoantibodies.

Original languageEnglish
Pages (from-to)1571-1576
Number of pages6
JournalArthritis and Rheumatism
Volume52
Issue number5
DOIs
Publication statusPublished - 2005 May

Fingerprint

Autoantibodies
Peptides
Dermatomyositis
Idiopathic Pulmonary Fibrosis
Connective Tissue Diseases
Interstitial Lung Diseases
Indirect Fluorescent Antibody Technique
Immunoprecipitation
Immunoblotting
Antibodies
Serum
Amyopathic dermatomyositis
Cytoplasm
Antigens

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. / Sato, Shinji; Hirakata, Michito; Kuwana, Masataka; Suwa, Akira; Inada, Shinichi; Mimori, Tsuneyo; Nishikawa, Takeji; Oddis, Chester V.; Ikeda, Yasuo.

In: Arthritis and Rheumatism, Vol. 52, No. 5, 05.2005, p. 1571-1576.

Research output: Contribution to journalArticle

Sato, S, Hirakata, M, Kuwana, M, Suwa, A, Inada, S, Mimori, T, Nishikawa, T, Oddis, CV & Ikeda, Y 2005, 'Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis', Arthritis and Rheumatism, vol. 52, no. 5, pp. 1571-1576. https://doi.org/10.1002/art.21023
Sato, Shinji ; Hirakata, Michito ; Kuwana, Masataka ; Suwa, Akira ; Inada, Shinichi ; Mimori, Tsuneyo ; Nishikawa, Takeji ; Oddis, Chester V. ; Ikeda, Yasuo. / Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. In: Arthritis and Rheumatism. 2005 ; Vol. 52, No. 5. pp. 1571-1576.
@article{f4fbd52c29304445ab34f3244d8bb043,
title = "Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis",
abstract = "Objective. To identify novel autoantibodies specific for dermatomyositis (DM), especially those specific for clinically amyopathic DM (C-ADM). Methods. Autoantibodies were analyzed by immunoprecipitation in 298 serum samples from patients with various connective tissue diseases (CTDs) or idiopathic pulmonary fibrosis (IPF). Antigen specificity of the sera was further examined by immunoblotting and indirect immunofluorescence (IF). The disease specificity and clinical features associated with the antibody of interest were determined. Results. Eight sera recognized a polypeptide of ∼140 kd (CADM-140 autoantigen) by immunoprecipitation and immunoblotting. Immunoreactivity was detected in the cytoplasm, and indirect IF revealed a granular or reticular pattern. Anti-CADM-140 antibodies were detected in 8 of 42 patients with DM, but not in patients with other CTDs or IPF. Interestingly, all 8 patients with anti-CADM-140 antibodies had C-ADM. Among 42 patients with DM, those with anti-CADM-140 autoantibodies had significantly more rapidly progressive interstitial lung disease (ILD) when compared with patients without anti-CADM-140 autoantibodies (50{\%} versus 6{\%}; P = 0.008). Conclusion. These results indicate that the presence of anti-CADM-140 autoantibodies may be a novel marker for C-ADM. Further attention should be directed to the detection of rapidly progressive ILD in those patients with anti-CADM-140 autoantibodies.",
author = "Shinji Sato and Michito Hirakata and Masataka Kuwana and Akira Suwa and Shinichi Inada and Tsuneyo Mimori and Takeji Nishikawa and Oddis, {Chester V.} and Yasuo Ikeda",
year = "2005",
month = "5",
doi = "10.1002/art.21023",
language = "English",
volume = "52",
pages = "1571--1576",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis

AU - Sato, Shinji

AU - Hirakata, Michito

AU - Kuwana, Masataka

AU - Suwa, Akira

AU - Inada, Shinichi

AU - Mimori, Tsuneyo

AU - Nishikawa, Takeji

AU - Oddis, Chester V.

AU - Ikeda, Yasuo

PY - 2005/5

Y1 - 2005/5

N2 - Objective. To identify novel autoantibodies specific for dermatomyositis (DM), especially those specific for clinically amyopathic DM (C-ADM). Methods. Autoantibodies were analyzed by immunoprecipitation in 298 serum samples from patients with various connective tissue diseases (CTDs) or idiopathic pulmonary fibrosis (IPF). Antigen specificity of the sera was further examined by immunoblotting and indirect immunofluorescence (IF). The disease specificity and clinical features associated with the antibody of interest were determined. Results. Eight sera recognized a polypeptide of ∼140 kd (CADM-140 autoantigen) by immunoprecipitation and immunoblotting. Immunoreactivity was detected in the cytoplasm, and indirect IF revealed a granular or reticular pattern. Anti-CADM-140 antibodies were detected in 8 of 42 patients with DM, but not in patients with other CTDs or IPF. Interestingly, all 8 patients with anti-CADM-140 antibodies had C-ADM. Among 42 patients with DM, those with anti-CADM-140 autoantibodies had significantly more rapidly progressive interstitial lung disease (ILD) when compared with patients without anti-CADM-140 autoantibodies (50% versus 6%; P = 0.008). Conclusion. These results indicate that the presence of anti-CADM-140 autoantibodies may be a novel marker for C-ADM. Further attention should be directed to the detection of rapidly progressive ILD in those patients with anti-CADM-140 autoantibodies.

AB - Objective. To identify novel autoantibodies specific for dermatomyositis (DM), especially those specific for clinically amyopathic DM (C-ADM). Methods. Autoantibodies were analyzed by immunoprecipitation in 298 serum samples from patients with various connective tissue diseases (CTDs) or idiopathic pulmonary fibrosis (IPF). Antigen specificity of the sera was further examined by immunoblotting and indirect immunofluorescence (IF). The disease specificity and clinical features associated with the antibody of interest were determined. Results. Eight sera recognized a polypeptide of ∼140 kd (CADM-140 autoantigen) by immunoprecipitation and immunoblotting. Immunoreactivity was detected in the cytoplasm, and indirect IF revealed a granular or reticular pattern. Anti-CADM-140 antibodies were detected in 8 of 42 patients with DM, but not in patients with other CTDs or IPF. Interestingly, all 8 patients with anti-CADM-140 antibodies had C-ADM. Among 42 patients with DM, those with anti-CADM-140 autoantibodies had significantly more rapidly progressive interstitial lung disease (ILD) when compared with patients without anti-CADM-140 autoantibodies (50% versus 6%; P = 0.008). Conclusion. These results indicate that the presence of anti-CADM-140 autoantibodies may be a novel marker for C-ADM. Further attention should be directed to the detection of rapidly progressive ILD in those patients with anti-CADM-140 autoantibodies.

UR - http://www.scopus.com/inward/record.url?scp=18644385765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644385765&partnerID=8YFLogxK

U2 - 10.1002/art.21023

DO - 10.1002/art.21023

M3 - Article

VL - 52

SP - 1571

EP - 1576

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -